Navigation Links
Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
Date:1/6/2011

through Lexicon's corporate website at www.lexpharma.com. An archived version of the presentation will be available for 30 days after the event.

About LX4211

LX4211 is an orally-delivered small molecule under development as a potential treatment for diabetes. LX4211 inhibits both sodium-glucose co-transporter type 1 (SGLT1) and sodium-glucose co-transporter type 2 (SGLT2).  SGLT2 is a transporter responsible for most of the glucose reabsorption performed by the kidney.  SGLT1 is a transporter responsible for glucose and galactose absorption in the gastrointestinal tract, and to a lesser extent than SGLT2, glucose reabsorption in the kidney.  For more information on LX4211 please visit www.lexpharma.com.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease.  Lexicon currently has four drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, and irritable bowel syndrome, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to the characterization of the results observed in the referenced clinical trial and prior clinical trials of LX4211 as positive or remarkable, the mechanism of action of LX4211, and the potential therapeutic and commercial potential of LX4211
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
2. Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
3. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
4. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
5. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results
6. Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs
7. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
8. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
9. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
10. Lexicon to Present at BIO International Convention
11. Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 Object recognition technology ... visually impaired and elderly. The VelaSense ® ... to lead more independent, productive and fulfilling lives. VelaSense ... will allow users to identify objects from a one ... as create customized object databases for personal use. ...
(Date:3/27/2015)... , March 27, 2015 Biopharmaceutical Industry ... biopharmaceutical industry comes out on top as the country,s ... new report  from ndp│analytics. According to the  analysis ... (R&D) investment over the last decade, accounting for 27 ... A Short Video on Medicare Part ...
(Date:3/27/2015)... , March 27, 2015 Zimmer Holdings, Inc. (NYSE and ... NexGen ® Complete Knee System. ... the 20 th year since Zimmer first introduced the NexGen ... market. To date, more than five million implantations of the NexGen ... history of the NexGen knee demonstrates the importance of design ...
Breaking Medicine Technology:VelaSense Object Recognition Technology for the Blind was unveiled at Baruch College's CCVIP 8th Annual Conference 2Week in Review: The Latest from PhRMA 2Zimmer Celebrates Key Milestones For NexGen Complete Knee System 2
(Date:3/28/2015)... New York, New York (PRWEB) March 28, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) involving devices manufactured by C.R. ... multidistrict litigation underway in U.S. District Court, Southern ... Jeffrey S. Grand, is serving on the Plaintiffs’ ... March 24th, the Court has granted certain defendants ...
(Date:3/28/2015)... Emergency Medical Care (EMC), a New ... recently commemorated its three-year anniversary of being the only ... to 24-hour urgent care, Emergency Medical Care offers its ... time, Emergency Medical Care’s Urgent Care NYC ... eye injuries, ear infections, fevers, insect bites, burns, animal ...
(Date:3/28/2015)... NY (PRWEB) March 28, 2015 An ... a problem which could prove critical to organizations that ... testing, a critical aspect of data security, is worsening ... industry data security report, every major category out of ... and penetration testing. “With all the craziness that has ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 Pitching speed, ... a history of shoulder and elbow injuries, according to new ... Medicine’s ( AOSSM ) Specialty Day. , “Our findings indicate ... a 20% increase in likelihood of a history of injury, ... with a 12% increase likelihood of a history of injury, ...
(Date:3/28/2015)... March 28, 2015 How best to ... growing field in orthopaedic medicine. While diagnostic hip injections ... confirm the pain etiology, research presented today at the ... Specialty Day suggests that pain relief from this diagnostic ... surgery. , “Our study looked to assess if ...
Breaking Medicine News(10 mins):Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2
... animal tests, researchers say , WEDNESDAY, June 2 (HealthDay ... become a treatment for a kind of brain tumor in ... occurs in about 20 percent of childhood brain cancer cases. ... the survival rate at five years to 70 percent, but ...
... pregnancy resulting from it, report shows , WEDNESDAY, June 2 ... teenagers -- or 4.3 million teen males and females -- ... report shows. , This continues a flattening trend ... 1995 and 2002, especially in males, said report author Joyce ...
... The eyes may or may not be windows to the soul, ... a peek into the eyes of cattle may become the basis ... causes Mad Cow Disease. That test could help prevent the disease ... tell-tale glow given off by eyes infected with the Mad Cow ...
... stuff that gives chili peppers their kick, may cause weight ... changes in the body. Their study, which could lead to ... of Proteome Research . Jong Won Yun and ... threat worldwide, linked to diabetes, high blood pressure, heart disease, ...
... ... teens, students in the Teens Turning Green chapter at San Rafael High School in Marin ... in their local community. This includes raising funds to replace unsustainable school products with ... ...
... anticancer drug, a delivery system based on a novel material ... reducing tumor growth than direct injection. That is the ... of the journal Cancer Research . "Effective targeted ... time now but it has been largely frustrated by the ...
Cached Medicine News:Health News:More Than 40% of U.S. Teens Have Had Sex 2Health News:More Than 40% of U.S. Teens Have Had Sex 3Health News:Students Target Toxic School Supplies 2Health News:Students Target Toxic School Supplies 3Health News:Nanosponge drug delivery system more effective than direct injection 2Health News:Nanosponge drug delivery system more effective than direct injection 3
The ImmunoWELL Borrelia M Test is an enzyme immunoassay (EIA) for the qualitative and/or semiquantitative detection of Borrelia burgdorferi,IgM antibodies in serum and is used as an aid in the diag...
... Mono-G Test is a qualitative enzyme ... to Epstein-Barr virus capsid antigen (EBV-VCA), ... (CMV), and Toxoplasma. When used in ... an aid in the serodiagnosis of ...
... ImmunoWELL VCA IgM Test is an ELISA method ... Epstein-Barr Virus viral capsid antigen (VCA) in human ... in conjunction with other testing such as the ... early antigen tests and/or heterophile tests, the results ...
... Borrelia DotBlot M Tests are qualitative enzyme ... Borrelia burgdorferi antibodies (IgG or IgM, respectively) ... these tests should be supplemented with a ... can be used to support a clinical ...
Medicine Products: